ConcertAI presented at the Morgan Stanley 22nd Annual Global Healthcare Conference at 10:00 a.m. ET on Wednesday, Sept. 4, 2024. Jeff Elton, PhD, chief executive officer at ConcertAI, presented at the conference. During the event, ConcertAI provided an update on the full implementation of its CARAai architecture supporting a new family of Gen AI CoPilots based on ConcertAI multi-modal RWD, ConcertAI advanced Large Language Models, Gen AI multi-agent technologies from SymphonyAI, and the first deployed AI workflows from the Company’s collaboration with NVIDIA.

Interested in downloading a summary of the presentation? Please fill out the form below:

About ConcertAI

ConcertAI is the leader in Predictive and Generative AI SaaS and Real-world Data research solutions and healthcare and life sciences. Our mission is to accelerate insights and outcomes for patients through research-ready data, CARA™ AI technologies, and scientific expertise in partnership with over 46 leading biomedical innovators, 2000 health care providers, and medical societies. CancerLinQ^® is an Initiative of ConcertAI, providing oncology providers ASCO aligned automated QOPI quality solutions and SmartLinQ analytic services. Headquartered in Cambridge, MA, ConcertAI has offices in Bangalore, Frankfurt, Philadelphia, Raleigh-Durham, Tokyo. For more information, visit us at https://www.concertai.com.